Episomal vectors for gene expression in mammalian cells

European Journal of Biochemistry

Volumn 267, Issue 18, 2000, Pages 5665-5678

  Van Craenenbroeck, Kathleen ^a   Vanhoenacker, Peter ^a   Haegeman, Guy ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Amplification; Episomal vectors; Gene therapy; Heterologous expression; Shuttle vector

Indexed keywords

BK VIRUS; EPISOME; EPSTEIN BARR VIRUS; EXPRESSION VECTOR; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE THERAPY; NONHUMAN; PAPILLOMA VIRUS; PLASMID; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SHUTTLE VECTOR;

ANIMALS; BK VIRUS; BOVINE PAPILLOMAVIRUS 1; CELL LINE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; MODELS, GENETIC; PLASMIDS; TRANSGENES;

BK POLYOMAVIRUS; BOVINAE; DNA VIRUSES; HUMAN HERPESVIRUS 4; MAMMALIA; PAPILLOMAVIRUS;

EID: 0033825821     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1327.2000.01645.x     Document Type: Review

References (203)

1. Vectors for high level expression of proteins in mammalian cells
2. Analysis of transcriptional regulatory regions of the human p53 gene in human cells using an EBV-derived shuttle vector
3. Receptor-based assays
4. Episomegenerated N-myc antisense RNA restricts the differentiation potential of primitive neuroectodermal cell lines
5. Receptor cloning and heterologous expression: Towards a new tool for drug discovery
6. Stable, high-level expression of human serotonin receptors in L929 cells using an inducible expression system
7. Optimized expression of serotonin receptors in mammalian cells using inducible expression systems
8. Integration of foreign DNA and its consequences in mammalian systems
9. Repeat-induced gene silencing in mammals
10. Insertion of foreign DNA into an established mammalian genome can alter the methylation of cellular DNA sequences
11. -) using an Epstein-Barr virus-derived cDNA expression vector
12. Extremely efficient gene transfection into lympho-hematopoietic cell lines by Epstein-Barr virus-based vectors
13. Epstein-Barr virus shuttle vector for stable episomal replication of cDNA expression libraries in human cells
14. A system utilizing Epstein-Barr virus-based expression vectors for the functional cloning of human fibroblast growth regulators
15. Developments in expression cloning
16. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system
17. pZ402, an improved SV40-based shuttle vector containing a T-antigen mutant unable to interact with wild-type p53
18. The potential of extrachromosomal replicating vectors for gene therapy
19. Safety-modified episomal vectors for human gene therapy
20. Expression cloning of a human DNA repair gene involved in xeroderma pigmentosum group C
21. Gene therapy: Promises
22. Papillomavirinae: The viruses and their replication
23. The primary structure and genetic organization of the bovine papillo-mavirus type I genome
24. New human papovavirus (B.K.) isolated from urine after renal transplantation
25. Studies with BK virus and monkey lymphotropic papovavirus
26. Association of BK and JC human polyomaviruses and SV40 with human tumors
27. Polyomaviruses
28. Nucleotide sequence of the DNA replication origin for human papovavirus BKV: Sequence and structural homology with SV40
29. The genome of human papovavirus BKV
30. Transactivation of BKV and SV40 early promoters by BKV and SV40 T-antigens
31. Polyomavirinae: The viruses and their replication
32. Analysis of the early regulatory region of the human Papovavirus BK
33. The late promoter of the human papovavirus BK is contained within the early promoter enhancer region
34. Linker scan analysis of the early regulatory region of human papovavirus BK
35. Analysis of origin of DNA replication of human papovavirus BK
36. An element of the BK virus enhancer required for DNA replication
37. Common and unique features of T antigens encoded by the polyomavirus group
38. The initiation of simian virus 40 DNA replication in vitro
39. The replication protein A binding site in simian virus 40 (SV40) T antigen and its role in the initial steps of SV40 DNA replication
40. Sequence requirements for the assembly of simian virus 40 T antigen and the T-antigen origin binding domain on the viral core origin of replication
41. BK virus-plasmid expression vector that persists episomally in human cells and shuttles into Escherichia coli
42. Factors affecting amplification of BK virus episomal vectors in human cells
43. New BK virus episomal vector for complementary DNA expression in human cells
44. Constitutive expression in human cells of herpes simplex virus type 1 glycoprotein B gene cloned in an episomal eukaryotic vector
45. Protection from Herpes Simplex Virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector
46. A novel BK virus-based episomal vector for expression of foreign genes in mammalian cells
47. High expression of exogenous cDNAs directed by HIV-1 long terminal repeat in human cells constitutively producing HIV-1 tat and adenovirus E1A/E1B
48. Efficient episomal expression vector for human transitional carcinoma cells
49. Systemic gene therapy: Biodistribution and long-term expression of a transgene in mice
50. Molecular integrity and usefulness of episomal expression vectors derived from BK and Epstein-Barr virus
51. Papillomaviruses
52. Transient replication of BPV-1 requires two viral polypeptides encoded by the E1 and E2 open reading frames
53. Rolling-circle replication of a high-copy BPV-1 plasmid
54. Random-choice replication of extrachromosomal bovine papillo-mavirus (BPV) molecules in heterogeneous, clonally derived BPV-infected cell lines
55. Cis and trans requirements for stable episomal maintenance of the BPV-1 replicator
56. Several different upstream promoter elements can potentiate transactivation by the BPV-1 E2 protein
57. Induction of structural changes in the bovine papillomavirus type 1 origin of replication by the viral E1 and E2 proteins
58. Characterization of the bovine papilloma virus plasmid maintenance sequences
59. Replication of plasmids derived from bovine papilloma virus type 1 and Epstein-Barr Virus in cells in culture
60. Amino-terminal domains of the bovine papillomavirus type 1, E1 and E2 proteins participate in complex formation
61. Co-operative interaction between the initiator E1 and the transcriptional activator E2 is required for replicator specific DNA replication of bovine papillomavirus in vivo and in vitro
62. Functional interactions between Papillomavirus E1 and E2 proteins
63. Binding of the E1 and E2 proteins to the origin of replication of bovine papillomavirus
64. Distinct roles of two binding sites for the bovine papillomavirus (BPV) E2 transactivator on BPV DNA replication
65. Bovine papilloma virus (BPV)-encoded E1 protein contains multiple activities required for BPV DNA replication
66. The E1 protein of bovine papilloma virus 1 is an ATP-dependent DNA helicase
67. The cellular DNA polymerase alpha-primase is required for papillomavirus DNA replication and associates with the viral E1 helicase
68. Modulation of bovine papillomavirus DNA replication by phosphorylation of the viral E1 protein
69. Segregation of viral plasmids depends on tethering to chromosomes and is regulated by phosphorylation
70. Bovine papillomavirus type 1 genomes and the E2 transactivator protein are closely associated with mitotic chromatin
71. Long-term episomal maintenance of bovine papillomavirus type 1 plasmids is determined by attachment to host chromosomes, which is mediated by the viral E2 protein and its binding sites
72. The bovine papilloma virus E1 protein has ATPase activity essential to viral DNA replication and efficient transformation in cells
73. In vitro tumorigenic transformation by a defined subgenomic fragment of bovine papilloma virus DNA
74. Bovine papilloma virus deoxyribonucleic acid: A novel eucaryotic cloning vector
75. Regulation of a metallo-thionein-growth hormone hybrid gene in bovine papilloma virus
76. Acquisition of interleukin-3 independence in FDC-P2 cells after transfection with the activated c-H-ras gene using a bovine papillomavirus-based plasmid vector
77. Lines of BPV-transformed murine cells that constitutively express influenza virus hemagglutinin
78. Complementation of a vesicular stomatitis virus glycoprotein G mutant with wild-type protein expressed from either a bovine papilloma virus or a vaccinia virus vector system
79. Replication of bovine papillomavirus vectors in murine cells
80. Copy number control of DNA replication in SV40-BPV hybrid replicons
81. Construction of a novel bovine papillomavirus vector without detectable transforming activity suitable for gene transfer
82. Epstein-Barr virus vectors for gene expression and transfer
83. Epstein-Barr virus strategy in normal and neoplastic B cells
84. Epstein-Barr virus: Mechanisms of oncogenesis
85. Molecular mechanisms of transformation by Epstein-Barr virus
86. Epstein-Barr virus
87. Epstein-Barr virus infection of human astrocyte cell lines
88. DNA-sequence and expression of the B95-B98 Epstein-Barr virus genome
89. Epstein-Barr virus and its replication
90. Herpesviridae
91. Viral latency and transformation: The strategy of Epstein-Barr virus
92. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells
93. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells
94. A putative origin of replication of plasmids derived from Epstein-Barr Virus is composed of two cis-acting components
95. Replication of latent Epstein-Barr virus genomes in Raji cells
96. Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells
97. Chromatin structure of Epstein-Barr virus
98. A nuclear matrix attachment region organizes the Epstein-Barr viral plasmid in Raji cells into a single DNA domain
99. Interactions of Epstein-Barr virus origins of replication with nuclear matrix in the latent and in the lytic phases of viral infection
100. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region
101. Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus DNA
102. Functional domains of Epstein-Barr virus nuclear antigen EBNA-1
103. Analysis of the Epstein-Barr virus origin of plasmid replication (oriP) reveals an area of nucleosome sparing that spans the 3' dyad
104. EBNA1 distorts oriP, the Epstein-Barr virus latent replication origin
105. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA
106. Rep*: A viral element that can partially replace the origin of plasmid DNA synthesis of Epstein-Barr virus
107. Identification of cellular factors that bind specifically to the Epstein-Barr virus origin of DNA replication
108. Constitutive binding of EBNA1 protein to the Epstein-Barr virus replication origin, oriP, with distortion of DNA structure during latent infection
109. The cellular proteins that bind specifically to the Epstein-Barr virus origin of plasmid DNA replication belong to a gene family
110. Multiple regions within EBNA1 can link DNAs
111. DNA looping between the origin of replication of Epstein-Barr virus and its enhancer site: Stabilization of an origin complex with Epstein-Barr nuclear antigen 1
112. Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication
113. Stabilization of the EBNA1 protein on the Epstein-Barr virus latent origin of DNA replication by a DNA looping mechanism
114. Interaction of Epstein-Barr virus nuclear antigen 1 with the viral latent origin of replication
115. EBNA1 can link the enhancer element to the initiator element of the Epstein-Barr virus plasmid origin of DNA replication
116. Mechanistic studies on the DNA linking activity of Epstein-Barr nuclear antigen 1
117. The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication
118. Role of EBNA-1 in arresting replication forks at the Epstein-Barr virus oriP family of tandem repeats
119. Single-stranded structures are present within plasmids containing the Epstein-Barr virus latent origin of replication
120. Isolation of human sequences that replicate autonomously in human cells
121. Improved EBV shuttle vectors
122. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus
123. Initiation of latent DNA replication in the Epstein-Barr virus genome can occur at sites other than the genetically defined origin
124. The plasmid replicon of EBV consists of multiple cis-acting elements that facilitate DNA synthesis by the cell and a viral maintenance element
125. The minimal replicator of Epstein-Barr virus oriP
126. Mapping EBNA-1 domains involved in binding to metaphase chromosomes
127. EBP2, a human protein that interacts with sequences of the Epstein-Barr virus nuclear antigen 1 important for plasmid maintenance
128. Trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1
129. Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus
130. P32/TAP, a cellular protein that interacts with EBNA-1 Epstein-Barr virus
131. Studies on the mechanism of DNA linking by Epstein-Barr virus nuclear antigen 1
132. The linking regions of EBNA1 are essential for its support of replication and transcription
133. Characterization of the genetic signals required for Epstein-Barr virus plasmid maintenance
134. Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells
135. Episomal expression of wild-type CFTR corrects cAMP-dependent chloride transport in respiratory epithelial cells
136. Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells
137. Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1
138. Epstein-Barr virus genomes in lymphoid cells: Activation in mitosis and chromosomal location
139. Utilization of an Epstein-Barr virus replicon as a eukaryotic expression vector
140. Isolation of a clone which induces expression of the gene encoding the human tumor necrosis factor receptor
141. Epstein-Barr virus-derived vectors for transient and stable expression of recombinant proteins
142. An expression system for mammalian amino acid transporters using a stably maintained episomal vector
143. Human recombinant alpha1 (V) collagen chain. Homotrimeric assembly and subsequent processing
144. Efficient gene transduction by Epstein-Barr-virus-based vectors coupled with cationic liposome and HVJ-liposome
145. Successful transfer of ADA gene in vitro into human peripheral blood CD34+ cells by transfecting EBV-based episomal vectors
146. Inhibition of protein kinase C alpha expression by antisense RNA in transfected Jurkat cells
147. Construction of an EBNA-producing line of well-differentiated human hepatoma cells and of appropriate Epstein-Barr virus-based shuttle vectors
148. Improved expression cloning using reporter genes and Epstein-Barr virus ori-containing vectors
149. Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus oriP sequences and EBNA1: Implications of the nuclear import of plasmids
150. Combinatorial gene expression using multiple episomal vectors
151. Rapid generation of stable cell lines expressing corticotropin-releasing hormone receptor for drug discovery
152. Amplified expression of tumor necrosis factor receptor in cells transfected with Epstein-Barr virus shuttle vector cDNA libraries
153. Differences in human cell lines to support stable replication of Epstein-Barr virus-based vectors
154. Gene transfer in vitro and in vivo with Epstein-Barr virus-based episomal vector results in markedly high transient expression in rodent cells
155. Epstein-Barr virus-based vectors that replicate in rodent cells
156. Long-term gene expression from autonomously replicating vectors in mammalian cells
157. Epstein-Barr-based episomal chromosomes shuttle 100 kb of self-replicating circular human DNA in mouse cells
158. The use of Epstein-Barr virus-based shuttle vectors in rat PC12 cells
159. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I
160. Long-term replication of Epstein-Barr virus-derived episomal vectors in the rodent cells
161. Selective extraction of Polyoma DNA from infected mouse cell cultures
162. Expression and rescuing of a cloned human tumour necrosis factor gene using an EBV-shuttle cosmid vector
163. High-frequency transformation of human repair-deficient cell lines by an Epstein-Barr virus-based cDNA expression vector
164. Human artificial episomal chromosomes for cloning large DNA fragments in human cells
165. Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome
166. Analysis of a YAC with human telomeres and oriP from Epstein-Barr virus in yeast and 293 cells
167. A system for shuttling 200-kb BAC/PAC clones into human cells. Stable extrachromosomal persistence and long-term ectopic gene activation
168. Long-term stability of large insert genomic DNA episomal shuttle vectors in human cells
169. Synthetic DNA delivery systems
170. Gene therapy: The first decade
171. Viral vectors for gene therapy
172. Stable episomal maintenance of yeast artificial chromosomes in human cells
173. Epstein-Barr virus vectors for gene delivery to B lymphocytes
174. A strategy for specific targeting of therapeutic agents to tumour cells of virus-associated cancers
175. A reporter system using a flow cytometer to detect promoter/enhancer activity in lymphoid cell lines
176. Use of EBV-based vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms
177. Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ liposomes
178. Enhanced expression of recombinant dystrophin following intramuscular injection of Epstein-Barr virus (EBV)-based mini-chromosome vectors in mdx mice
179. BK virus large T antigen: Interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control
180. Transient gene expression control: Effects of transfected DNA stability and trans-activation by viral early proteins
181. Efficient transcriptional activation of many simple modular promoters by simian virus 40 large T antigen
182. Mechanisms of transcriptional regulation of cellular genes by SV40 large T- and small t-antigens
183. Chromosomal aberrations induced by BK virus T antigen in human fibroblasts
184. A possible contributory role of BK virus infection in neuroblastoma development
185. Interaction of the transcription factor TFIID with simian virus 40 (SV40) large T antigen interferes with replication of SV40 DNA in vitro
186. Simian virus 40 large T antigen J domain and Rb-binding motif are sufficient to block apoptosis induced by growth factor withdrawal in a neural stem cell line
187. A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells
188. Mitotic stability of an episomal vector containing a human scaffold/matrix-attached region is provided by association with nuclear matrix
189. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade
190. Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus
191. EBNA-1, the major nuclear antigen of Epstein-Barr virus, resembles 'RGG' RNA binding proteins
192. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice
193. New host cell system for regulated simian virus 40 DNA replication
194. Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene
195. High level transient gene expression in human lymphoid cells by SV40 large T antigen boost
196. Use of simian virus 40 replication to amplify Epstein-Barr Virus shuttle vectors in human cells
197. A two-plasmid system for transient expression of cDNAs in primate cells
198. High recombination rate of an Epstein-Barr virus-simian virus 40 hybrid shuttle vector in human cells
199. Simian virus (SV40) large T antigen-dependent amplification of an Epstein-Barr virus-SV40 hybrid shuttle vector integrated into the human HeLa cell genome
200. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein
201. An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency
202. A novel herpesvirus amplicon system for in vivo gene delivery
203. The Epstein-Barr nuclear antigen (BamHI K antigen) is a single-stranded DNA binding phosphoprotein